<DOC>
	<DOCNO>NCT02542215</DOCNO>
	<brief_summary>To evaluate efficacy , safety , pharmacokinetics ( PK ) liquid cobiprostone prevent oral mucositis , administer topically oral mucosa via spray duration radiation chemotherapy ( RT/CT ) .</brief_summary>
	<brief_title>Cobiprostone Prevention Oral Mucositis Subjects With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Recentlydiagnosed ( within last 6 month ) , histologicallydocumented , nonmetastatic squamous cell carcinoma oral cavity and/or oropharynx amenable radiotherapy concurrent chemotherapy definitive treatment modality . Clinical treatment plan call minimum 50 Gy cumulative radiation dose administer via continuous course external beam irradiation oral cavity and/or oropharynx via intensitymodulated radiation therapy [ IMRT ] and/or imageguided radiation therapy [ IGRT ] , combine conventional weekly/triweekly cisplatin carboplatin chemotherapy regimen . Subject receive prior radiation head neck region ( +/ chemotherapy ) . Subject prior invasive malignancy , unless diseasefree minimum 3 year . Subject metastatic disease ( M1 ) Stage IVC . Subject presence mucosal ulceration oral mucositis screen develops prior randomization , and/or unhealed wound remain surgical resection and/or excisional biopsy procedure . Subject use preexist feed tube nutritional support study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>